XML 60 R51.htm IDEA: XBRL DOCUMENT
v3.19.1

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |  |  | 1 Months Ended | 3 Months Ended
--- | --- | --- | --- | ---
Sep. 04, 2018 | Aug. 08, 2017 | Nov. 16, 2017 | Mar. 31, 2019
SkyPharm [Member] | April 18, 2018 [Member] | Advisory Agreement [Member] |  |  |  |
Term of operating lease |  |  |  | 10 years
Annually operating lease amount |  |  |  | $ 104,000
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] |  |  |  |
Operating lease periodic payment |  |  |  | $ 1,500
Common stock shares reserved |  |  |  | 200,000
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Preclinical Trials [Member] |  |  |  |
Common stock shares reserved |  |  |  | 50,000
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | conclusion of Phase I testing [Member] |  |  |  |
Common stock shares reserved |  |  |  | 50,000
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase III testing [Member] |  |  |  |
Common stock shares reserved |  |  |  | 50,000
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase II testing [Member] |  |  |  |
Common stock shares reserved |  |  |  | 50,000
Private Placement [Member] |  |  |  |
Commitments and contingencies description |  | (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering. |  |
Cash commission description | In connection with the Company's September 4, 2018 Note offering, the Agent received a cash commission for this transaction of $140,000, equal to seven (7%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase seven (7%) percent of the shares of Common Stock issued or issuable in this offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 26,056 shares); however, will receive seven (7%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or March 4, 2019. |  | In connection with the Company's November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or as of May 16, 2018. |

X
- References No definition available. + Details
Name: | COSM_AnnuallyOperatingLeaseAmount
Namespace Prefix: | COSM_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_CashCommissionDescription
Namespace Prefix: | COSM_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_LesseeLeasingArrangementsOperatingLeaseTermOfContract
Namespace Prefix: | COSM_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_OperatingLeasePeriodicPayment
Namespace Prefix: | COSM_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Describes all significant commitments and obligations resulting from franchise agreements, including a description of the services that the franchisor has agreed to provide for agreements that have not yet been substantially performed. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 952 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109207840&loc=SL109207861-203207 + Details
Name: | us-gaap_CommitmentsFromFranchiseAgreements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate number of common shares reserved for future issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=COSM_SkyPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=COSM_AprilOneEightTwoZeroOneEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=COSM_AdvisoryAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=COSM_AnastasiosTsekasAndOlgaPartheneaGeorgatwouMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=COSM_OnOctoberOneTwoThousandSixteenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=COSM_IntellectualPropertySaleAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPreclinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPhaseOneTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPhaseThreeTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPhaseTwoTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |